COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

被引：0
|
作者：
Wilson, M. [1 ]
Lucas, A. [1 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.864
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI22
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN'S DISEASE IN THE UNITED KINGDOM (UK)
    Robson, R. E.
    Vanoli, A.
    Tolley, K.
    VALUE IN HEALTH, 2018, 21 : S455 - S456
  • [2] Cost-effectiveness of Natalizurnab in patients with Crohn's Disease who have failed TNF-alpha inhibitor therapy
    Wolf, D.
    Sands, B.
    Panjabi, S.
    Niecko, T.
    Hass, S.
    Lacey, L.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S38 - S38
  • [3] Cost-effectiveness of natalizumab in patients with Crohn's disease who have failed Anti-TNFα therapy
    Sands, Bruce
    Wolf, Douglas
    Panjabi, Sumeet
    Niecko, Timothy
    Hass, Steven
    Lacey, Loretto
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S401 - S402
  • [4] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Sands, Bruce E.
    Wolf, Douglas C.
    Panjabi, Sumeet
    Niecko, Timothy
    Hass, Steven
    Lacey, Loretto
    Spencer, Mike
    GASTROENTEROLOGY, 2008, 134 (04) : A638 - A638
  • [5] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Panjabi, S.
    Niecko, T.
    Hass, S. L.
    Lacey, L.
    Spencer, M. D.
    VALUE IN HEALTH, 2008, 11 (03) : A85 - A85
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [7] Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn's Disease
    Kappelman, Michael
    Lewis, James D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica L.
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Long, Millie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S676 - S676
  • [8] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY
    Arhan, M.
    Tezel, H. A.
    Toruner, M.
    Bilaloglu, B.
    Koral, S.
    Ozer, E.
    VALUE IN HEALTH, 2018, 21 : S145 - S145
  • [9] Comparative effectiveness of vedolizumab and ustekinumab in Crohn's Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource
    Desoki, R.
    Balendran, K.
    Kapizioni, C.
    Shawky, R.
    Parkes, M.
    Raine, T.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I118 - I118
  • [10] An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients
    Kawalec, Pawel
    Mocko, Pawel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (02) : 101 - 111
12345